Business Weekly has covered LongeVC’s recent investment in Constructive Bio, a Cambridge-based synthetic biology company developing genome writing and sustainable biomanufacturing technologies. The article highlights the company’s efforts to replace solvent-heavy chemical synthesis with aqueous-based processes for high-demand peptides like semaglutide and tirzepatide, supported by a £1.1M Innovate UK grant. LongeVC’s support marks a step forward in translating foundational research into scalable solutions for the next generation of biologics.
Read the full article here.
Read the full article here.